

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re the Application of:

HOLE, Doug, et al.

Serial No.: 10/658,665

Filed: September 9, 2003

**For: USE OF NITRIC OXIDE AND A
DEVICE IN THE THERAPEUTIC
MANAGEMENT OF PATHOGENS IN
MAMMALS**

Group Art Unit: 3761

Examiner: DEAK, Leslie R.

Confirmation No.: 2000

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(c)(2)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, the items identified in the attached Supplemental Information Disclosure Statement ("IDS") Form PTO/SB/08 (also form PTO-1449) are brought to the attention of the Patent Office. Copies of the cited references are submitted herewith.

The items identified in this Supplemental IDS may or may not be "material" pursuant to 37 C.F.R. § 1.56. The submission thereof by Applicant is not to be construed as an admission

CERTIFICATE OF MAILING
(37 C.F.R. § 1.8a)

06/19/2007 AAHMADI 00000016 501597 18658665
01 FC:1806 180.00 DA

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in a box addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

June 15, 2007
Date of Deposit

Carolyn L. Evans
Carolyn L. Evans

that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. § 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicant as such.

The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR


☒ the fee set forth in 37 CFR 1.17(p).

The Commissioner is hereby authorized to charge any fees required by the filing of these papers to Sidley Austin LLP's Deposit Account No. **50-1597**.


Respectfully submitted,

SIDLEY AUSTIN LLP

Dated: June 15, 2007

By: 
Carissa A. Tener
Reg. No. 52,278

SIDLEY AUSTIN LLP
555 W. Fifth Street, Suite 4000
Los Angeles, California 90013
(213) 896-6000
Customer No. 34492



PTO/SB/08a (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/P

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet

1

of

19

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US- 3,036,584	05/1962	Lee, A. S. J.	
	2	US- 3,192,106	06/1965	Bracken et al.	
	3	US- 4,127,121	11/1978	Westenskow et al.	
	4	US- 4,191,952	03/1980	Schreiber et al.	
	5	US- 4,224,941	09/1980	Stivala	
	6	US- 4,328,823	05/1982	Schreiber	
	7	US- 4,336,798	06/1982	Beran	
	8	US- 4,345,612	08/1982	Koni et al.	
	9	US- 4,442,856	04/1984	Betz et al.	
	10	US- 4,608,041	08/1986	Nielsen	
	11	US- 4,611,590	09/1986	Ryschka et al.	
	12	US- 4,770,168	09/1988	Rusz et al.	
	13	US- 4,905,685	03/1990	Olsson et al.	
	14	US- 4,954,526	09/1990	Keefer	
	15	US- 5,154,697	10/1992	Loori	
	16	US- 5,155,137	10/1992	Keefer et al.	
	17	US- 5,159,924	11/1992	Cegielski et al.	
	18	US- 5,197,462	03/1993	Falb et al.	
	19	US- 5,396,882	03/1995	Zapol	
	20	US- 5,423,313	06/1995	Olsson et al.	
	21	US- 5,427,797	06/1995	Frostell et al.	
	22	US- 5,485,827	01/1996	Zapol et al.	
	23	US- 5,514,204	05/1996	Sheu et al.	
	24	US- 5,519,020	05/1996	Smith et al.	
	25	US- 5,536,241	07/1996	Zapol	
	26	US- 5,531,218	07/1996	Krebs	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 2 of 19

U. S. PATENT DOCUMENTS (Continued)

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	27	US- 5,558,083	09/1996	Bathe et al.	
	28	US- 5,570,683	11/1996	Zapol	
	29	US- 5,615,669 A	04/1997	Olsson et al.	
	30	US- 5,632,981	05/1997	Saavedra et al.	
	31	US- 5,648,101	07/1997	Tawashi, R.	
	32	US- 5,650,442	07/1997	Mitchell et al.	
	33	US- 5,651,358	07/1997	Briend et al.	
	34	US- 5,676,963	10/1997	Keefer et al.	
	35	US- 5,688,236	11/1997	Gragg	
	36	US- 5,692,497	12/1997	Schnitzer et al.	
	37	US- 5,700,830	12/1997	Korthuis et al.	
	38	US- 5,713,349	02/1998	Kearney	
	39	US- 5,722,392	03/1998	Skimming et al.	
	40	US- 5,732,693	03/1998	Bathe et al.	
	41	US- 5,765,548	06/1998	Perry	
	42	US- 5,789,447	08/1998	Wink, Jr. et al.	
	43	US- 5,810,795	09/1998	Westwood	
	44	US- 5,814,666	09/1998	Green et al.	
	45	US- 5,814,667	09/1998	Mitchell et al.	
	46	US- 5,823,180	10/1998	Zapol	
	47	US- 5,834,030	11/1998	Bolton	
	48	US- 5,837,736	11/1998	Mitchell et al.	
	49	US- 5,839,433 A	11/1998	Higgenbottom	
	50	US- 5,840,759	11/1998	Mitchell et al.	
	51	US- 5,845,633	12/1998	Psaros	
	52	US- 5,873,359	02/1999	Zapol et al.	
	53	US- 5,885,621	03/1999	Head et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	3	of	19
-------	---	----	----

U. S. PATENT DOCUMENTS (Continued)

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	54	US- 5,904,938	05/1999	Zapol et al.	
	55	US- 5,918,596	07/1999	Heinonen	
	56	US- 5,597,880	09/1999	Igo et al.	
	57	US- 6,000,403	12/1999	Cantwell	
	58	US- 6,019,100	02/2000	Alving et al.	
	59	US- 6,060,020	05/2000	Piuk et al.	
	60	US- 6,063,407	05/2000	Zapol et al.	
	61	US- 6,067,983	05/2000	Stenzler	
	62	US- 6,071,254	06/2000	Augustine	
	63	US- 6,073,627	06/2000	Sunnen	
	64	US- 6,083,209	07/2000	Marasco, Jr.	
	65	US- 6,089,229	07/2000	Bathe et al.	
	66	US- 6,103,275	08/2000	Seitz et al.	
	67	US- 6,109,260	08/2000	Bathe	
	68	US- 6,110,895	08/2000	Rodgers et al.	
	69	US- 6,125,846	10/2000	Bathe et al.	
	70	US- 6,131,572	10/2000	Heinonen	
	71	US- 6,142,147	11/2000	Head et al.	
	72	US- 6,158,434	12/2000	Lugtigheid et al.	
	73	US- 6,160,021	12/2000	Lerner et al.	
	74	US- 6,164,276	12/2000	Bathe et al.	
	75	US- 6,190,704	02/2001	Murrell	
	76	US- 6,200,558 B1	03/2001	Saavedra et al.	
	77	US- 6,232,336 B1	05/2001	Hrabie et al.	
	78	US- 6,270,779 B1	08/2001	Fitzhugh et al.	
	79	US- 6,358,536 B1	03/2002	Thomas	
	80	US- 6,379,660 B1	04/2002	Saavedra et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 4 of 19

U. S. PATENT DOCUMENTS (Continued)

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	81	US- 6,432,077	08/2002	Stenzler	
	82	US- 6,472,390 B1	10/2002	Stamler et al.	
	83	US- 6,494,314 B1	12/2002	Lamborne et al.	
	84	US- 6,511,991 B2	01/2003	Hrabie et al.	
	85	US- 6,555,058 B2	04/2003	Kamibayashi et al.	
	86	US- 6,571,790 B1	06/2003	Weinstein	
	87	US- 6,581,599 B1	06/2003	Stenzler	
	88	US- 6,601,580	08/2003	Block et al.	
	89	US- 6,673,338 B1	01/2004	Arnold et al.	
	90	US- 6,703,046 B2	03/2004	Fitzhugh et al.	
	91	US- 6,706,274 B2	03/2004	Herrmann et al.	
	92	US- 6,715,485 B1	04/2004	Djupeisland	
	93	US- 6,747,062 B2	06/2004	Murrell	
	94	US- 6,750,254 B2	06/2004	Hrabie et al.	
	95	US- 6,758,214 B2	07/2004	Fine et al.	
	96	US- 6,780,849 B2	08/2004	Herrmann et al.	
	97	US- 6,786,217	09/2004	Stenzler	
	98	US- 6,793,644	09/2004	Stenzler	
	99	US- 6,796,966 B2	09/2004	Thomas	
	100	US- 6,811,965 B2	11/2004	Vodovotz et al.	
	101	US- 6,867,194 B2	03/2005	Wang et al.	
	102	US- 6,887,485 B2	03/2005	Fitzhugh et al.	
	103	US- 6,911,478 B2	06/2005	Hrabie et al.	
	104	US- 6,920,876 B2	07/2005	Miller al.	
	105	US- 6,938,357 B2	09/2005	Hauch	
	106	US- 6,949,530 B2	09/2005	Hrabie et al.	
	107	US- 7,048,951 B1	05/2006	Seitz et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	5	of	19
-------	---	----	----

U. S. PATENT DOCUMENTS (Continued)

107

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	108	US- 7,105,502 B2	09/2006	Arnold et al.	
	109	US- 7,118,767 B2	10/2006	Kim et al.	
	110	US- 7,122,018 B2	10/2006	Stenzler et al.	
	111	US- 7,199,154 B2	04/2007	Berthelette et al.	
	112	US- 2002/0069877	06/2002	Villareal	
	113	US- 2002/0082566	06/2002	Stenzler	
	114	US- 2002/0119115	08/2002	Keefer et al.	
	115	US- 2002/0138051	09/2002	Hole et al.	
	116	US- 2002/0155164	10/2002	Figley et al.	
	117	US- 2002/0156416	10/2002	Stenzler	
	118	US- 2003/0165578	09/2003	Murrell	
	119	US- 2002/0169202	11/2002	Kazutami et al.	
	120	US- 2003/0039697	02/2003	Zhao et al.	
	121	US- 2003/0150457	08/2003	Miller et al.	
	122	US- 2003/0203915	10/2003	Fang et al.	
	123	US- 2003/0215528	11/2003	Graham et al.	
	124	US- 2003/0228564	12/2003	Edirch et al.	
	125	US- 2004/0009238	01/2004	Miller et al.	
	126	US- 2004/0043026	03/2004	Tuan et al.	
	127	US- 2004/0081580	04/2004	Hole et al.	
	128	US- 2004/0112378	06/2004	Djupesland	
	129	US- 2004/0131703	07/2004	Bach et al.	
	130	US- 2004/0163647	08/2004	Figley et al.	
	131	US- 2004/0180863	09/2004	Hrabie et al.	
	132	US- 2004/0259840	12/2004	Herrmann et al.	
	133	US- 2005/0079148	04/2005	Fitzhugh et al.	
	134	US- 2005/0016427	01/2005	Memory	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application-form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	6	of	19
-------	---	----	----

U. S. PATENT DOCUMENTS (Continued)

134

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	135	US- 2005/0137521	06/2005	Stenzler	
	136	US- 2005/0142217	06/2005	Adams et al.	
	137	US- 2005/0148566	07/2005	Waterhouse et al.	
	138	US- 2005/0171066	08/2005	Shami	
	139	US- 2005/0191372	09/2005	Stenzler et al.	
	140	US- 2005/0217668	10/2005	Figley et al.	
	141	US- 2005/0217679	10/2005	Miller et al.	
	142	US- 2005/0251117	11/2005	Anderson et al.	
	143	US- 2005/0265958	12/2005	West et al.	
	144	US- 2005/0288260	12/2005	Hrabie et al.	
	145	US- 2006/0008529	01/2006	Meyerhoff et al.	
	146	US- 2006/0068031	03/2006	Miller et al.	
	147	US- 2006/0147553	07/2006	Miller et al.	
	148	US- 2007/0065473	03/2007	Miller et al.	
	149	US- 2007/0086954	04/2007	Miller et al.	
	150	US- 2007/0088316	04/2007	Stenzler et al.	
	151	US- 2007/0104653	05/2007	Miller et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 ^d
		Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known)				
	152	EP 0640356 A1	03/1995	Siemens Elema AB		
	153	EP 0640357 A1	03/1995	Rydgren, Göran		
	154	EP 0659445 A1	06/1995	Bathe, D. et al.		
	155	EP 0659445 B1	06/1995	Bathe, D. et al.		
	156	EP 1243278 A2	09/2002	Bolton, A.		
	157	FR 2656218	06/1991	Gérard, M.		✓

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

 American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 7 of 19

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known)				
	158	JP3-139364	06/1991	Mamoru, H. et al.		✓
	159	JP3-207365	09/1991	Ishikawajima-Harima		✓
	160	WO 92/17445	10/1992	Goldstein, J. et al.		
	161	WO 93/15779	08/1993	Frankland, N.		
	162	WO 93/17741	09/1993	Zapol, W.		
	163	WO 95/09612	04/1995	Green, S. et al.		
	164	WO 96/00006	01/1996	Billiar, T. et al.		
	165	WO 96/22803	08/1996	Stenquist		
	166	WO 96/25184	08/1996	Zapol, W. et al.		
	167	WO 96/31217	10/1996	Stamler, J. S. et al.		
	168	WO 98/01142	01/1998	Blaise, G.		
	169	WO 99/49921	10/1999	Head, C. et al.		
	170	WO 00/07653	02/2000	Henley, C. et al.		
	171	WO 01/65935 A1	09/2001	Vodovotz, Y., et al.		
	172	WO 00/30659 (CA 99/01123)	06/2000	Miller, C.		
	173	WO 02/056864 A2	07/2002	Herrman, R., et al.		
	174	WO 03/066109 A1	08/2003	Edrich, R., et al.		
	175	WO 2005/060603 A3	07/2005	Garvey, D., et al.		
	176	WO 2005/110052 A3	11/2005	Murray, B. et al.		
	177	WO 2005/110441 A2	11/2005	Stenzler, A. et al.		
	178	Abstract for DE 003713396A1	11/1998	Zeuch et al.		✓
	179	KR 202066 with English Abstract	06/1999	Han et al.		✓

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 8 of 19

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	180	Ray, James D. et al., "A New Method of Preparing Nitric Oxide," Contribution from the Department of Chemistry, Stanford University (1956)	
	181	Shank, J. L. et al., "The Effect of Nitric Oxide on Bacteria," Applied Microbio, No. 10, 189-189 (1962)	
	182	Norman, C. et al., "Nitrogen Oxides in Tobacco Smoke," Nature, Vol. 205, No. 4971, pp. 915-916, (February 1965)	
	183	Canetti, G., "Present aspects of bacterial resistance in tuberculosis," Am. Rev. Respir. Dis. 92:687-703 (1965)	
	184	Bass, H. et al., "Regional structure and function in brochiectasis," Am. Rev. Respir. Dis. 97:598-609 (1968)	
	185	Contractor, A. M. et al., "Development and Evaluation of an Inhalation Aerosol of Nitroglycerin," Journal of Pharmaceutical Sciences, Vol. 63, No. 6, pp. 907-911 (June 1974)	
	186	Oda, H. et al., "Nitrosyl-Hemoglobin Formation in the Blood of Animals Exposed to Nitric Oxide," Archives of Environmental Health, Vol. 30, No. 7, pp. 453-456 (September 1975)	
	187	Katsuki, S. et al., "Stimulation of Guanylate Cyclase by Sodium Nitroprusside, Nitroglycerin and Nitric Oxide in Various Tissue Preparations and Comparison to the Effects of Sodium Azide and Hydroxylamine," Journal of Cyclic Nucleotide Research, Vol. 3, pp. 23-25 (1977)	
	188	Hugod, C., "Effect of exposure of 43 PPM nitric oxide and 3.6 PPM nitrogen dioxide on rabbit lung," Arch. Occup. Environ. Health 42:159-167 (1979)	
	189	Yoshida, J. et al., "Metabolic Fate of Nitric Oxide," Int Arch Occup Environ Health, Vol. 46, No. 1, pp. 71-77 (April 1980)	
	190	Borland, C., "The Fate of Inhaled Nitric Oxide," Clinical Science, Abstract No. 104, p. 37P (1983)	
	191	Mancinelli et al., "Effects of Nitric Oxide and Nitrogen Dioxide on Bacterial Growth," Applied and Environmental Microbiology, vol. 46, No. 1, pp. 198-202 (July 1983)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet

9

of

19

192	Demling, R. H. et al., "The Pulmonary and Systemic Response to Recurrent Endotoxemia in the Adult Sheep," Surgery, Vol. 100, No. 5, pp. 876-883 (November 1986)
193	Higenbottam, T., "Primary Pulmonary Hypertension," British Medical Journal, Vol. 293, PP. 1456-1457 (December 1986)
194	Higenbottam, T. et al., "Primary Pulmonary Hypertension," British Medical Journal, Vol. 294, p. 705 (March 1987)
195	Palmer, R.M.J. et al., "Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor," Nature, Vol. 327, pp. 524-526 (June 1987)
196	Ignarro, L. J. et al., "Endothelium-Derived Relaxing Factor Produced and Released From Artery and Vein is Nitric Oxide," Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, No. 24, pp. 9265-9269 (December 1987)
197	Higenbottam, T. W. et al., "Inhaled 'Endothelium Derived-Relaxing Factor' (EDRF) in Primary Hypertension (PPH)," Abstract, American Review of Respiratory Disease, Suppl., Vol. 137, No. 4, Part 2, p. 107 (April 1988)
198	Ignarro, L. J. et al., "Endothelium-Derived Relaxing Factor and Nitric Oxide Possess Identical Pharmacologic Properties as Relaxants of Bovine Arterial and Venous Smooth Muscle," The Journal of Pharmacology and Experimental Therapeutics, Vol. 246, No. 1, pp.
199	Dinh-Xuan, A. T. et al., "Non-Prostanoid Endothelium-Derived Vasoactive Factors," The Journal of International Medical Research, Vol. 17, pp. 305-315 (1989)
200	Borland, C. D. R. et al., "A Simultaneous Single Breath Measurement of Pulmonary Diffusing Capacity with Nitric Oxide and Carbon Monoxide," The European Respiratory Journal, Vol. 2, No. 1, pp. 56-63 (January 1989)
201	Buga, G. M. et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," European Journal of Pharmacology, Vol. 161, No. 1, pp. 61-72, (February 1989)
202	Garg, U. C. et al., "Nitric Oxide-generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells," The Journal of Clinical Investigation, Vol. 83, No. 5, pp. 1774-1777 (May 1989)
203	Meyer, M. et al., "Nitric Oxide (NO), a New Test Gas for Study of Alveolar-capillary Diffusion," The European Respiratory Journal, Vol. 2, No. 6, pp. 494-496 (June 1989)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	10	of	19
-------	----	----	----

204	Dinh-Xuan, A. T. et al., "Primary Pulmonary Hypertension: Diagnosis, Medical and Surgical Treatment," Vol. 84, pp. 189-197 (1990)
205	Stavert, D. M. et al., "Nitric Oxide and Nitrogen Dioxide as Inducers of Acute Pulmonary Injury When Inhaled at Relatively High Concentrations for Brief Periods," Inhalation Toxicology 2:53-67 (1990)
206	Moinard, J. et al., "Determination of Lung Capillary Blood Volume and Membrane Diffusing capacity in Patients with COLD using the NO-CO Method," The European Respiratory Journal, Vol. 3, pp. 318-322 (1990)
207	Archer, S. L., "Comparison of the Hemodynamic Effects of Nitric Oxide and Endothelium-Dependent Vasodilators in Intact Lungs," Journal of Applied Physiology, Vol. 68, No. 2, pp. 735-747 (February 1990)
208	Meyer, M. et al., "Pulmonary Diffusing Capacities for Nitric Oxide and carbon Monoxide Determined by Rebreathing in Dogs," Journal of Applied Physiology, Vol. 68, No. 6, pp. 2344-2357 (June 1990)
209	Vane, J. R. et al., "Regulatory Functions of the Vascular Endothelium," The New England Journal of Medicine, Vol. 323, No. 1, pp. 27-36 (July 1990)
210	Higenbottam, T. et al., "Has the Treatment of Asthma Improved?" Chest, Vol. 98, No. 3, pp. 706-712 (September 1990)
211	Swami, A. et al., "The Pulmonary Physician and critical Care: 2. The Injury Lung: Conventional and Novel Respiratory Therapy," Thorax, Vol. 47, pp. 555-562 (1992)
212	Bult, H. et al., "Chronic Exposure to Exogenous Nitric Oxide May Suppress its Endogenous Release and Efficacy," Journal of Cardiovascular Pharmacology, Vol. 17, Suppl. 3, pp. S79-S82 (1991)
213	Frostell, C. et al., "Inhaled Nitric Oxide, A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction," Circulation Journal of the American Heart Association, Vol. 83, pp. 2083-2047 (1991)
214	Hendrickson, D.A. et al., "Regents and Stains," Manual of Clinical Microbiology, 5 th Ed., American Society for Microbiology, pp. 1289-1314 (1991)
215	Cremona, g. et al., "Endothelium-derived Relaxing Factor and the Pulmonary Circulation," Lung, Vol. 169, pp. 185-202 (1991)
216	Falke, K. et al., "Inhaled Nitric Oxide Selectively Reduces Pulmonary Hypertension in Severe ARDS and Improves Gas Exchange as well as right Heart Ejection fraction - A Case Report," Abstract 248, Am. Rev. Respir. Dis., Vol. 143 (1991)
Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

 American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	11	of	19
-------	----	----	----

217	Fratucci, M. D., "Inhaled Nitric Oxide – A Selective Pulmonary Vasodilator of Heparin-Protamine Vasoconstriction in Sheep," Anesthesiology, Vol. 75, pp. 990-999 (1991)
218	Denis, M., "Interferon—Gamma-treated Murine Macrophages Inhibit Growth of Tubercle Bacilli via the Generation of Reactive Nitrogen Intermediates," Cellular Immunology, Vol. 132, No. 1, pp. 150-157 (January 1991)
219	Dinh-Xuan, A. T. et al., "Impairment of Endothelium-Dependent Pulmonary-Artery Relaxation in Chronic Obstructive Lung Disease," The New England Journal of Medicine, Vol. 324, No. 22, pp. 1539-1547 (May 1991)
220	Frostell, C. et al., "Inhaled Nitric Oxide – A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction," Circulation, Vol. 83, No. 6 (June 1991)
221	Moncada, S. et al., "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," Pharmacological Reviews, Vol. 43, No. 2 (June 1991)
222	Frostell, C. et al., "Inhaled Nitric Oxide Dilates Human Hypoxic Pulmonary Vasoconstriction Without Causing Systemic Vasodilation," Anesthesiology, The Journal of The American Society of Anesthesiologists, Inc., Vol. 75, No. 3A, Abstract A989 (September 1991)
223	Girard, C. et al., "Inhaled Nitric Oxide (NO) in Pulmonary Hypertension Following Mitral Valve Replacement," Anesthesiology, The Journal of The American Society of Anesthesiologists, Inc., Vol. 75, No. 3A, Abstract A983 (September 1991)
224	Roberts, J. D. et al., "Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator for the Treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN)," Abstract 1279, Circulation, Vol. 84, No. 4, p. II-321 (October 1991)
225	Pepke-Zaba, J. et al., "Inhaled Nitric Oxide as a Cause of Selective Pulmonary Vasodilatation in Pulmonary Hypertension," The Lancet, Vol. 338, No. 8776, pp. 1173-1174 (November 1991)
226	Radomski, M. W., et al., "Human Colorectal Adenocarcinoma Cells: Differential Nitric Oxide Synthesis Determines Their Ability to Aggregate Platelets," Cancer Research, Vol. 51, pp. 6073-6078 (November 15, 1991)
227	Johns, R. A., "EDRF/Nitric Oxide – The Endogenous Nitrovasodilator and a New cellular Messenger," Anesthesiology, The Journal of The American Society of Anesthesiologists, Inc., Vol. 75, No. 6, pp. 927-931 (December 1991)
228	Pearl, R. G., "The Pulmonary Circulation," Anesthesiology, Vol. 5, pp. 848-854 (1992)
229	Chan, J. et al., "Killing of Virulent Mycobacterium Tuberculosis by Reactive Nitrogen Intermediates Produced by Activated Murine Macrophages," J. Exp. Med. 175:1111-1122 (April 1992)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

 American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 12 of 19

230	Rossiant, R. et al., "Successful Treatment of Severe Adult Respiratory Distress Syndrome with Inhaled Nitric Oxide," American Review of Respiratory Disease, Suppl., Vol. 145, No. 4, Part 2, p. A80 (April 1992)
231	Rossiant, R. et al., "Inhaled Nitric Oxide in Contrast to Infused Prostacyclin Selectively Reduces Pulmonary Hypertension and Improves Gas Exchange in Severe ARDS," Abstract, American Review of Respiratory Disease, Suppl., Vol. 145, No. 4, Part 2, p. A185
232	Bigatello, L. M., "Inhaled Nitric Oxide is a Selective Pulmonary Vasodilator in Septic Patients with Severe ARDS," Abstract, American Review of Respiratory Disease, Suppl., Vol. 145, No. 4, Part 2, p. A185 (April 1992)
233	Snyder, S. H. et al., Biological Roles of Nitric Oxide," Scientific American, Vol. 266, No. 5, pp. 68-77 (May 1992)
234	Foubert, L., "Safety Guidelines for Use of Nitric Oxide," The Lancet, Vol. 339, No. 8809, pp. 1615-1616 (June 1992)
235	Messent, M. et al., "Pharmacotherapy in Lung Injury," Thorax, Vol. 47, No. 7, pp. 651-656 (July 1992)
236	Barash, P. et al., "Anesthesiology," The Journal of the American Medical Association, Vol. 268, No. 3, pp. 335-337 (July 1992)
237	Dupuy, P. M. et al., "Bronchodilator Action of Inhaled Nitric Oxide in Guinea Pigs," J. Clin. Invest., Vol. 90, pp. 421-428 (August 1992)
238	Kinsella, J. P. et al., "Hemodynamic Effects of Exogenous Nitric Oxide in Ovine Transitional Pulmonary Circulation," American Journal of Physiology: Heart and Circulatory Physiology, Vol. 32, No. 3, pp. H875-H880 (September 1992)
239	Roberts, J. D. et al., "Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn," The Lancet, Vol. 340, pp. 818-819 (October 1992)
240	Kinsella, J. P. et al., "Low-Dose Inhalational Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn," The Lancet, Vol. 340, pp. 819-820 (October 1992)
241	Girard, C. et al., "Inhaled Nitric Oxide After Mitral Valve Replacement in Patients with Chronic Pulmonary Artery Hypertension," Anesthesiology, The Journal of the American Society of Anesthesiologists, Inc., Vol. 77, No. 5, pp. 880-883 (November 1992)
242	Kacmarek, R. M., "Nitric Oxide as a Bronchodilator in Methacholine Induced Bronchospasm in Mild Asthmatics," Abstract (1993)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 13 of 19

243	Blomqvist, H. et al., "Enhanced Pneumonia Resolution by Inhalation of Nitric Oxide?" Acta Anaesthesiol Scand, Vol. 37, pp. 110-114 (1993)
244	Buga, G. M. et al., "Negative Feedback Regulation of Endothelial Cell Function by Nitric Oxide," Circulation Research, Journal of the American Heart Association, 73:808-812 (1993)
245	Higenbottam, T., "Inhaled Nitric Oxide: A Magic Bullet?" Quarterly Journal of Medicine, Vol. 86, pp. 555-558 (1993)
246	Stenqvist, O. et al., "Evaluation of a New System for Ventilatory Administration of Nitric Oxide," Acta Anaesthesiologica Scandinavica, pp. 687-691 (1993)
247	Rossaint, R. et al., "Inhaled Nitric Oxide For The Adult Respiratory Distress Syndrome," New England Journal of Medicine, Vol. 328, pp. 399-405 (February 1993)
248	Maragos, C. M., et al., "Nitric Oxide/Nucleophile Complexes Inhibit the <i>in Vitro</i> Proliferation of A375 Melanoma Cells via Nitric Oxide Release," Cancer Research, Vol. 53, pp. 564-568 (February 01, 1993)
249	Pearl, R. G., "Inhaled Nitric Oxide - The Past, The Present and the Future," Anesthesiology, Vol. 78, No. 3, pp. 413-416 (March 1993)
250	Assreuy, J. et al., "Feedback Inhibition of Nitric Oxide Synthase Activity by Nitric Oxide," British Journal of Pharmacology, Vol. 108, pp. 883-837 (March 1993)
251	Higenbottam, T. et al., "Highlights on Pulmonary Hypertension: A Commentary," The European Respiratory Journal, Vol. 6, No. 7, pp. 932-933 (July 1993)
252	Haworth, S. G., "Pulmonary Hypertension in Childhood," The European Respiratory Journal, Vol. 6, No. 7, pp. 1037-1043 (July 1993)
253	Higenbottam, T. et al., "Acute and Chronic Hypoxic Pulmonary Hypertension," The European Respiratory Journal, Vol. 6, No. 8, pp. 1207-1212 (September 1993)
254	Mansch, R. et al., "Simulation of Microbiologically and chemically Influenced corrosion of Natural Sandstone," Abstract, ASTM Special Technical Publication, 203-16; 1 pg. (1994)
255	Lowenstein, C. J. et al., "Nitric Oxide: a Physiologic Messenger," Annals of Internal Medicine, Vol. 120, Issue 3, pp. 227-237 (February 1994)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet

14

of

19

256	Dong, Z., et al., "Inverse Correlation Between Expression of Inducible Nitric Oxide Synthase Activity and Production of Metastasis in K-1735 Murine Melanoma Cells," Cancer Research, Vol. 54, pp. 789-793 (February 01, 1994)
257	Butt, A. Y. et al., "New Therapies for Primary Pulmonary Hypertension," Chest, Vol. 105, No. 2, pp. 21S-25S (February 1994)
258	Foubert, L. et al., "Nitric Oxide in Pulmonary Hypertension: Therapeutic Considerations," Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 3, Suppl. 2, p. 41 (June 1994)
259	Snow, D. et al., "Inhaled Nitric Oxide in Pulmonary Hypertension," Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 3, Suppl. 2, Abstract No. 127 (June 1994)
260	O'Brien, L. et al., "Strains of Mycobacterium Tuberculosis Differ in Susceptibility to Reactive Nitrogen Intermediates In Vitro, Infection and Immunity, Vol. 62, No. 11, pp. 5187-5190 (August 1994)
261	Young, J. D., "A Universal Nitric Oxide Delivery System," British Journal of Anaesthesia, Vol. 73, No. 4, pp. 700-702 (October 1994)
262	Hagenah, Jens-Uwe, "The Use of Nitric Oxide (NO) in Intensive Care Ventilation," Drägerwerk Aktiengesellschaft, pp. 1 and 3-36
263	Hanson, S. R., et al., "Nitric Oxide Donors: A Continuing Opportunity in Drug Design," Nitric Oxide Biochemistry, Molecular Biology, and Therapeutic Implications, Advances in Pharmacology, Vol. 34, pp. 383-398 (1995)
264	Chan, J. et al., "Effects of Nitric Oxide Synthase Inhibitors on Murine Infection with Mycobacterium Tuberculosis," Infection and Immunity, Vol. 63, No. 2., pp. 736-740 (February 1995)
265	DeGroote, M. A., et al., "NO Inhibitions: Antimicrobial Properties of Nitric Oxide," Clinical Infectious Diseases, Vol. 21, Suppl. 2, pp. S162-S165 (October 1995)
266	Body, S. C., M.D. et al., "Nitric Oxide: Delivery, Measurement, and Clinical Application," Journal of Cardiothoracic and Vascular Anesthesia, Vol. 9, No. 6, pp. 748-763 (December 1995)
267	Higenbottam, T. et al., "The Treatment of Primary Pulmonary Hypertension," Therapeutic Applications of Iloprost, A Volume in the Clinical Monograph Series, pp. 35-41 (April 1995)
268	Szabo, C., "The Pathophysiological Role of Peroxynitrite in Shock, Inflammation and Ischemia-Reperfusion Injury," Shock, Vol. 6, No. 2, pp. 79-88 (1996)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 15 of 19

269	Higenbottam, T., "Nitric Oxide and the Lung," Horizons in Medicine, No. 7 pp. 203-224 (1996)
270	Young, J. D. et al., "Delivery and Monitoring of Inhaled Nitric Oxide," Intensive Care Medicine, Vol. 22, No. 1, pp. 77-86 (January 1996)
271	Mellgren, K., et al., "Nitric Oxide in the Oxygenator Sweep Gas Reduces Platelet Activation During Experimental Perfusion," The Annals of Thoracic Surgery, Vol. 61, No. 4, pp. 1194-1198 (April 1996)
272	Ramnarine, S. I., et al., "Nitric Oxide Inhibition of Basal and Neurogenic Mucus Secretion in Feerrete Trachea <i>in Vitro</i> ," British Journal of Pharmacology, Vol. 118 (4), pp. 998-1002 (June 1996)
273	Channick, R. N., M.D. et al., "Pulsed Delivery of Inhaled Nitric Oxide to Patients with Primary Pulmonary Hypertension," Chest, The Cardiopulmonary and Critical Care Journal, Vol. 109, No. 6, pp. 1545-1549 (June 1996)
274	Hudome, S. M., M.D. et al., "Precise Control of Nitric Oxide Concentration in the Inspired Gas of Continuous Flow Respiratory Devices," Pediatric Pulmonology, Vol. 22, No. 3, pp. 182-187 (September 1996)
275	Cuthbertson, B. H. et al., "Inhaled Nitric Oxide," The Lancet, Vol. 348, No. 9039, pp. 1447-1448 (November 1996)
276	Gerlach, H. et al., "Low Levels of Inhaled Nitric Oxide in Acute Lung Injury," Nitric Oxide and the Lung, Vol. 98, Chapter 14, pp. 271-283 (1997)
277	Dupuy, P. M. et al., "Bronchial Effects of Nitric Oxide," Nitric Oxide and the Lung, Vol. 98, Chapter 15, pp. 285-311 (1997)
278	Leopold, J. A. et al., "New Developments in Nitrovasodilator Therapy," Vascular Medicine, Vol. 2, No. 3 (1997)
279	Rook, G. A. W., "Intractable Mycobacterial Infections Associated with Genetic Defects in the Receptor for Interferon Gamma: What Does This Tell Us About Immunity to Mycobacteria?" Thorax, Vol. 52 (Suppl. 3), pp. S41-S46 (1997)
280	Katayama, Y. et al., "Inhaled Nitric Oxide and Arterial Oxygen Tension in Patients with chronic Obstructive Pulmonary Disease and Severe Pulmonary Hypertension," Thorax, The Journal of the British Thoracic Society, Vol. 52, pp. 120-124 (1997)
281	Neonatal Inhaled Nitric Oxide Study Group, "Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory Failure," New England Journal of Medicine, 336(9):597-604 (February 1997)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate syn bols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	16	of	19
-------	----	----	----

282	Roberts, J. D. et al., "Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn," New England Journal of Medicine, 336:605-610 (February 1997)
283	Imanaka, H., M.D. et al., "Inaccuracies of Nitric Oxide Delivery Systems During Adult Mechanical Ventilation," Anesthesiology, Vol. 86, No. 3, pp. 676-688 (March 1997)
284	Marriott, H. et al., "The Role of Nitric Oxide in Respiratory Disease," Schweiz Med Wochenschr, Vol. 127, pp. 709-714 (April 1997)
285	Nozaki, Y. et al., "Mechanism of Nitric Oxide-Dependent Killing of Mycobacterium bovis BCG in Human Alveolar Macrophages," Infection and Immunity, Vol. 65, pp. 3644-3647 (September 1997)
286	Hess, D., RRT, Ph.D. et al., "Delivery Systems for Inhaled Nitric Oxide," Respiratory Care Clinics of North America, Vol. 3, No. 3, pp. 371-410 (September 1997)
287	Hoehn T., M.D. et al., "Effect of Therapeutic Concentrations of Nitric Oxide on Bacterial Growth in Vitro," Crit Care Med, Vol. 26, No. 11, pp. 1857-1862 (1998)
288	Bauer, J. A. et al., "Evaluation of Linear Polyethyleneimine/Nitric Oxide Adduct on Wound Repair: Therapy Versus Toxicity, The Wound Healing Society, pp. 569-577 (1998)
289	Pizzichini, M. M. M. et al., "Asthma and Natural Colds: Inflammatory Indices in Induced Sputum: A Feasibility Study," American Journal of Respiratory Critical Care Medicine, Vol. 158, pp. 1178-1184 (1998)
290	Higenbottam, T. et al., "Primary and Secondary Pulmonary Hypertension," Seminars in Respiratory and Critical Care Medicine, Vol. 19, No. 1, pp. 91-95 (1998)
291	Long R. et al., "Pulmonary Tuberculosis Treated with Directly Observed Therapy: Serial Changes in Lung Structure and Function," Chest, Vol. 113, pp. 933-943 (1998)
292	Klein, M.D. et al., "Nitric Oxide Delivery Systems," Acta Anaesthesiologica Scandinavica, pp. 274-275 (1998)
293	Francoe, M, RRT et al., "Inhaled Nitric Oxide: Technical Aspects of Administration and Monitoring," Critical Care Medicine, Vol. 26, No. 4, pp. 782-796 (April 1998)
294	Keefer, L. K., "Nitric Oxide-Releasing Compounds: From Basic Research to Promising Drugs," The American Chemical Society, Vol. 28, pp. 30-35 (August 1998)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

 American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet 17 of 19

295	Ivy, D. D., M.D. et al., "Acute Hemodynamic Effects of Pulsed Delivery of Low Flow Nasal Nitric Oxide in Children with Pulmonary Hypertension," The Journal of Pediatrics, Vol. 133, No. 3, pp. 453-456 (September 1998)
296	Hiesmayr, M. J. et al., "Performance of Proportional and Continuous Nitric Oxide Delivery Systems During Pressure- and Volume-Controlled Ventilation," The British Journal of Anaesthesia, Vol. 81, No. 4, pp. 544-552 (October 1998)
297	Katayama, Y., M.D. et al., "Minimizing the Inhaled Dose of NO With Breath-by-Breath Delivery of Spikes of Concentrated Gas," Circulation, Journal of the American Heart Association, Vol. 98, No. 22 (December 1998)
298	Higenbottam, T. et al., "Treatments for Severe Pulmonary Hypertension," The Lancet, Vol. 353, No. 9150, pp. 338-340 (January 1999)
299	Long, R. et al., "Mycobacteriocidal Action of Exogenous Nitric Oxide," Antimicrobial Agents and Chemotherapy, Vol. 43, No. 2, pp. 403-405, (February 1999)
300	Schofnagl, H. et al., "Proportional and Continuous NO Delivery Systems," British Journal of Anaesthesia, Vol. 82, No. 4, pp. 647-653 (April 1999)
301	Rimmelzwaan, G. F. et al., "Inhibition of Influenza Virus Replication by Nitric Oxide," Journal of Virology, American Society for Microbiology, Vol. 73, No. 10, pp. 8880-8883 (October 1999)
302	Webert, K. E., M.D. et al., "Effects of Inhaled Nitric Oxide In A Rat Model of <i>Pseudomonas aeruginosa</i> Pneumonia," Crit Car Med, Vol. 28, No. 7, pp. 2397-2405 (2000)
303	Tamaoki, J., M.D., et al., "Impairment of Airway Mucociliary Transport in Patients with Sinobronchial Syndrome: Role of Nitric Oxide," Journal of Aerosol Medicine, Vol. 13, No. 3, pp. 239-244 (November 2000)
304	Long et al., "Treatment of Sputum-Smear Positive Pulmonary Tuberculosis With Inhaled Nitric Oxide," 2001-Abstract Form to the ATS 2001 San Francisco, May 18-23, 2001 (faxed Mar. 27, 2001)
305	Frank, S., et al., "Nitric Oxide Drives Skin Repair: Novel Functions Of An Established Mediator," Kidney International, Vol. 61, pp. 882-888 (2002)
306	Imada, M., et al., "Functional Roles of Nasal Nitric Oxide in Nasal Patency and Mucociliary Function," ACTA Oto-Laryngologica, Vol. 122, No. 5, pp. 513-519 (July 2002)
307	Kirov, M. Y., M.D., et al., "Combination of Intravenously Infused Methylene Blue and Inhaled Nitric Oxide Ameliorates Endotoxin-Induced Lung Injury in Awake Sheep," Critical Care Medicine, Vol. 31, No. 1, pp. 179-186 (January 2003)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet

18

of

19

308	Shami, P. J., et al., JS-K, A Glutathione/Glutathione S-Transferase-activated Nitric Oxide Donor of the Diazeniumdiolate Class with Potent Antineoplastic Activity," Molecular Cancer Therapeutics, Vol. 2, pp. 409-417 (April 2003)
309	Counter-Defendant's First Amended Responses to Counterclaimant's Second Set of Interrogatories Relating to Counterclaims (Nos. 19-38) (October 2003)
310	Miller, Chris C. et al., "Treatment of Chronic Nonhealing Leg Ulceration with Gaseous Nitric Oxide: A Case Study"; Journal of Cutaneous Medicine and Surgery, pp. 233-238 (2004)
311	Vijh, A. K., "High Infectious Burden, Low Cancer Incidence, and Early Malignancy in Developing Countries: A Molecular Hypothesis in Term of the Role of Nitric Oxide," Medical Hypotheses, Vol. 63, pp. 208-210 (February 2004)
312	Sanders, S. P. et al., "Role of Nasal Nitric Oxide in the Resolution of Experimental Rhinovirus Infection," Journal of Allergy and Clinical Immunology, Vol. 113, No. 4, pp. 697-702 (April 2004)
313	Schmidt, I. et al., "Physiologic and Proteomic Evidence for a Role of Nitric Oxide in Biofilm Formation by <i>Nitrosomonas europaea</i> and Other Ammonia Oxidizers; Journal of Bacteriology, Vol. 186, No. 9, pp. 2781-2788 (May 2004)
314	Reynolds, M. M., et al., "Nitric Oxide-Releasing Hydrophobic Polymers: Preparation, Characterization, and Potential Biomedical Applications," Free Radical Biology & Medicine, The Official Journal for the Society for Free Radical Biology and Medicine, Vol. 37, No. 7, pp. 926-936 (October 2004)
315	Lechner, M., et al., "Inducible Nitric Oxide Synthase (iNOS) in Tumor Biology: The Two Sides of the Same Coin," Seminars in Cancer Biology, Vol. 15, pp. 277-289 (2005)
316	Ghaffair, A., et al., "A Direct Nitric Oxide Gas Delivery System for Bacterial and Mammalian Cell Cultures," Nitric Oxide Biology and Chemistry, Vol. 12, pp. 129-140 (2005)
317	Proud, D., "Nitric Oxide and The Common Cold," Journal of Allergy and Clinical Immunology, Vol. 5, pp. 37-42 (2005)
318	Nablo, B. J., et al., Inhibition of Implant-Associated Infections Via Nitric Oxide Release," Science Direct, Biomaterials, Vol. 26, pp. 6984-6990 (May 2005)
319	McMullin, B. B., MSc RRT, et al., "The Antimicrobial Effect of Nitric Oxide on the Bacteria That Cause Nosocomial Pneumonia in Mechanically Ventilated Patients in the Intensive Care Unit," Respiratory Care, Vol. 50, No. 11, pp. 1451-1456 (November 2005)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

American LegalNet, Inc.
www.FormsWorkflow.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,665
Filing Date	September 9, 2003
First Named Inventor	HOLE, Doug
Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	24647-81901 (0-03-192)

Sheet	19	of	19
-------	----	----	----

320	Hurford, W. E.; Nitric Oxide As A Bacterial Agent: Is The Cure Worse Than The Disease?; Respiratory Care, Vol. 50, No. 11, pp. 1428-1429 (November 2005)	
321	Katayama, Y. et al., "A Minimal Dose of Inhaled Nitric Oxide Delivered As A 'Spike' of Small Volume in Early Inhalation," Section of Respiratory Medicine, Division of Clinical Sciences, The Medical School, University of Sheffield (23 pages)	
322	Turchi, J. J., "Nitric Oxide and Cisplatin Resistance: NO Easy Answers," PNAS, Vol. 103, No. 12, pp. 4337-4338 (March 21, 2006)	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option

 American LegalNet, Inc.
www.FormsWorkflow.com




Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: HOLE, Doug, et al.
Serial No.: 10/658,665
For: USE OF NITRIC OXIDE AND A DEVICE IN THE THERAPEUTIC
MANAGEMENT OF PATHOGENS IN MAMMALS
Filed: September 9, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Attorney: Carissa A. Tener
Docket No.: 24647 ~~1000~~-81901 (0-03-192)
Date of Deposit: June 15, 2007

Enclosures: 1) Information Disclosure Statement Transmittal; 2) Information Disclosure
Citation PTO/SB/08a and 08b with copies of cited art; and 3) Return Postcard.



LA1 942509v.1

